drugset
drugset / Trial / NCT07163624

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

NCT07163624 ↗

Phase 2 Completed 211 enrolled The United Bio-Technology (Hengqin) Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.

Timeline

Start
2025-03-22
Primary completion
2025-11-21
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 1 mg Subcutaneous
Subject UBT251 Unknown 2 mg Subcutaneous
Subject UBT251 Unknown 4 mg Subcutaneous
Subject UBT251 Unknown 6 mg Subcutaneous

Indications

type 2 diabetes mellitus